THE INTERNATIONAL PROGNOSTIC INDEX IS ASSOCIATED WITH OUTCOMES IN DIFFUSE LARGE B CELL LYMPHOMA AFTER CAR T CELL THERAPY

類似資料

• DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality
  著者:: Wudhikarn, Kitsada, 等
  出版事項: (2020)
• Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma
  著者:: Wudhikarn, Kitsada, 等
  出版事項: (2020)
• Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management
  著者:: Pennisi, Martina, 等
  出版事項: (2020)
• Safety and Feasibility of Chimeric Antigen Receptor T Cell Therapy after Allogeneic Hematopoietic Cell Transplantation in Relapsed/ Refractory B Cell Non-Hodgkin’s Lymphoma
  著者:: Jain, Tania, 等
  出版事項: (2019)
• Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma
  著者:: Lin, Richard J., 等
  出版事項: (2020)